Eli Lilly and Company (India) has officially launched Mounjaro (tirzepatide) in the Indian market following marketing authorization from the Central Drugs Standard Control Organization (CDSCO). This innovative, once-a-week injectable therapy is designed for chronic weight management and type 2 diabetes treatment, offering a unique mechanism of action that targets both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors.

Transforming Obesity and Type 2 Diabetes Care

Mounjaro represents a first-of-its-kind therapy, leveraging dual incretin receptor activation to aid weight loss and glycemic control. The drug is indicated as an adjunct to a reduced-calorie diet and increased physical activity for adults with:

• Obesity (Body Mass Index (BMI) of 30 kg/m² or greater)
• Overweight (BMI of 27 kg/m² or greater) with at least one weight-related comorbidity, such as hypertension, dyslipidemia, or cardiovascular conditions.
• Type 2 diabetes mellitus, as a supplement to diet and exercise, to improve glycemic control.

The company has introduced Mounjaro in single-dose vials in 5 mg vial and 2.5 mg vials. 

Addressing India’s Rising Burden of Metabolic Disorders

India faces a significant dual burden of diabetes and obesity, with over 101 million people diagnosed with diabetes and nearly 100 million affected by obesity. Many adults struggle with suboptimal glycemic control, making innovative treatment options like Mounjaro crucial in managing these conditions effectively.

Winselow Tucker, President and General Manager, Lilly India, emphasized the company’s dedication to improving healthcare outcomes. He stated, “Our mission to enhance the quality of life for individuals dealing with obesity and diabetes in India is reflected in our commitment to delivering groundbreaking medicines. The introduction of Mounjaro is a testament to this mission and our goal of fostering a healthier nation.”

Clinical Validation and Efficacy

Mounjaro has been extensively evaluated through global clinical programs, including SURMOUNT-1 trials, which focused on chronic weight management and SURPASS trials, which examined its effectiveness in type 2 diabetes treatment. 

The drug has demonstrated the ability to reduce food intake, body weight, and fat mass while improving metabolic parameters, including lipid utilization. Studies indicate that patients receiving Mounjaro experience significant improvements in glycemic control, weight reduction, and appetite regulation.

Also Read: Narayana Health, W Health Ventures, and 2070 Health Join Forces to Launch Everhope Oncology with $10M Seed Investment

A Step Forward in Metabolic Health

Obesity, recognized as a chronic, relapsing disease, is associated with over 200 health complications, including hypertension, cardiovascular disease, and obstructive sleep apnea. 

Dr. Manish Mistry, Senior Medical Director, Lilly India, highlighted the need for innovative treatments, stating, “Obesity and diabetes pose severe health risks, necessitating effective and sustained treatment solutions. Mounjaro offers healthcare providers a powerful tool to address these challenges and revolutionize metabolic health management.”

As Eli Lilly continues to expand its portfolio in India, the launch of Mounjaro signifies a major milestone in tackling diabetes and obesity. With its once-weekly administration and dual receptor action, it is poised to offer a novel therapeutic approach for millions struggling with these metabolic conditions.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!